Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Lancet Neurol. 2015 Aug 10;14(10):1002–1009. doi: 10.1016/S1474-4422(15)00178-7

Figure 1. Details of methods and workflow.

Figure 1

Orange boxes denote steps of the workflow specific to the PPMI study while the purple box denotes validation phase analyses in additional sample series outside of PPMI. Abbreviations include: Parkinson’s Progression Marker Initiative (PPMI), Parkinson’s Disease Biomarkers Program (PDBP), Parkinson’s Associated Risk Study (PARS), 23andMe, Longitudinal and Biomarker Study in PD (LABS-PD), and Morris K. Udall Parkinson’s Disease Research Center of Excellence (Penn-Udall), University of Pennsylvania Smell Identificaiton Test (UPSIT), genetic risk score (GRS), subjects with dopamine transporter imaging scans showing no evidence of dopaminergic deficit (SWEDD), area under the curve (AUC).